DESIGN FOR FDA: A PREDICTIVE MODEL FOR THE FDA'S DECISION TIME FOR MEDICAL DEVICES
暂无分享,去创建一个
Gül E. Okudan Kremer | Lourdes A. Medina | Richard A. Wysk | Saylisse Dávila | R. Wysk | G. Kremer | Saylisse Dávila | L. Medina
[1] Mohan V. Tatikonda,et al. Technology novelty, project complexity, and product development project execution success: a deeper look at task uncertainty in product innovation , 2000, IEEE Trans. Engineering Management.
[2] A. Griffin. The Effect of Project and Process Characteristics on Product Development Cycle Time , 1997 .
[3] David Wilemon,et al. An empirical investigation of complexity and its management in new product development , 2009, Technol. Anal. Strateg. Manag..
[4] Jack E. Lemons,et al. New Products and Standards , 1996 .
[5] Achim Zeileis,et al. Conditional variable importance for random forests , 2008, BMC Bioinformatics.
[6] Abbie Griffin,et al. Modeling and measuring product development cycle time across industries , 1997 .
[7] P. Murmann. Expected development time reductions in the German mechanical engineering industry , 1994 .
[8] Gül E. Okudan Kremer,et al. An Analysis of Critical Factors in Medical Device Development to Design for FDA , 2012 .
[9] S. Bartlett Foote. Medical technology development: limiting regulation , 1996 .
[10] A. Griffin. Metrics for Measuring Product Development Cycle Time , 1993 .
[11] Shelby D. Reed,et al. Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices , 2007, Journal of General Internal Medicine.
[12] Achim Zeileis,et al. Bias in random forest variable importance measures: Illustrations, sources and a solution , 2007, BMC Bioinformatics.
[13] Andy Liaw,et al. Classification and Regression by randomForest , 2007 .
[14] Lourdes A. Medina,et al. A Review of Design for X Methods for Medical Devices: The Introduction of a Design for FDA Approach , 2011 .
[15] George C. Runger,et al. Feature Selection with Ensembles, Artificial Variables, and Redundancy Elimination , 2009, J. Mach. Learn. Res..
[16] Buddy D. Ratner,et al. Biomaterials Science: An Introduction to Materials in Medicine , 1996 .
[17] Ian Robinson,et al. Benefits of and barriers to involving users in medical device technology development and evaluation , 2007, International Journal of Technology Assessment in Health Care.
[18] Philip H Long,et al. Medical Devices in Orthopedic Applications , 2008, Toxicologic pathology.
[19] J. Friedman. Greedy function approximation: A gradient boosting machine. , 2001 .
[20] Kannan Srinivasan,et al. New product development structures and time-to-market , 1997 .
[21] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[22] Michael Simons,et al. Medical Device Development: From Prototype to Regulatory Approval , 2004, Circulation.
[23] John Hutton,et al. Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective. , 2003, Health policy.
[24] M. R. Millson,et al. Managing innovation in the medical device industry , 1998, IEMC '98 Proceedings. International Conference on Engineering and Technology Management. Pioneering New Technologies: Management Issues and Challenges in the Third Millennium (Cat. No.98CH36266).
[25] K. B. Hendricks,et al. Delays in new product introductions and the market value of the firm: the consequences of being late to the market , 1997 .
[26] David Anderson,et al. Proving experience speeds medical device time to market , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.